Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
Recruiting · NCT06909604 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
HER2 expression of PET imaging
What this trial is about
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Aged ≥18 years old; ECOG 0 or 1;
- Patients with HER2 positive or low tumors;
- Receives neoadjuvant therapy
- Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;
- Life expectancy \> 3 months -
Exclusion criteria
- Significant hepatic or renal dysfunction;
- Is pregnant or ready to pregnant;
- Cannot keep their states for half an hour;
- Refused to join the clinical research;
- Suffering from claustrophobia or other mental disorders;
- Any other situation that researchers considered it unsuitable to participate in the trial.
Where it is running
1 location listed.
- Peking University Cancer Hospital & Institute - Beijing, China